As the global population ages, macular degeneration (MD), also called age-related macular degeneration, is becoming an important public health issue. Increasing resources are being directed at better understanding the disease and the development of new therapeutic options. Gone are the days when patients were told “there is nothing more we can offer you” with almost certainty that severe vision loss would result.
